Human Genome (HGSI) Affirms New Albiglutide from Glaxo (GSK)
Get Alerts HGSI Hot Sheet
Join SI Premium – FREE
Human Genome (Nasdaq: HGSI) reports that GlaxoSmithKline (NYSE: GSK) issued an update on its Phase III of Albiglutide. For more color, click here.
Albiglutide was created by HGS using its proprietary albumin-fusion technology, and was licensed to GSK in 2004. HGS is entitled to fees and milestone payments that could amount to as much as $183 million – including $33.0 million received to date – in addition to single-digit net royalties on worldwide sales if albiglutide is commercialized.
All inquiries regarding the albiglutide Phase 3 data announced today should be directed to the contacts provided by GSK.
Albiglutide was created by HGS using its proprietary albumin-fusion technology, and was licensed to GSK in 2004. HGS is entitled to fees and milestone payments that could amount to as much as $183 million – including $33.0 million received to date – in addition to single-digit net royalties on worldwide sales if albiglutide is commercialized.
All inquiries regarding the albiglutide Phase 3 data announced today should be directed to the contacts provided by GSK.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Applied Therapeutics Inc. (APLT) Provides FDA Update on PDUFA Date for Govorestat
- BigBear.ai (BBAI) Announces Resignations of Raluca Dinu and Avi Katz
- Empire Petroleum (EP) Announces Modification of Terms of Previously Announced Rights Offering
Create E-mail Alert Related Categories
Corporate News, FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!